March 21, 2023, CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE. [Read more…]
Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling
SAN FRANCISCO–Tempo Bioscience, Inc. (“Tempo”), a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: [Read more…]
GOOD Meat, the World’s First-to-Market Cultivated Meat Company, Receives U.S. FDA Clearance
Acclaimed chef José Andrés will be first in the country to serve GOOD Meat’s chicken
ALAMEDA, Calif.–GOOD Meat, the cultivated meat division of food technology company Eat Just, Inc., announced today that it has received a “no questions” letter from the U.S. Food and Drug Administration as part of one of the agency’s first pre-market consultations for a new kind of meat, poultry and seafood made from cells instead of raised and slaughtered animals. The letter means that following a careful and rigorous evaluation, the FDA has accepted the company’s conclusion that its first poultry product, cultivated chicken, is safe to eat. [Read more…]
$3.0m CRC-P grant to VivaZome Therapeutics and Partners for Customised Exosome Therapy
Collaboration with La Trobe University, The University of Queensland, Australian National University, Cytiva and SeerPharma Pty Ltd
19 January 2023, Melbourne, Australia – VivaZome Therapeutics Pty Ltd (“VivaZome”) is delighted to announce that it has been awarded an Australian Government Round 13 CRC-P grant of $3.0m in support of the project “Customised exosomes – the future of regenerative medicine”. [Read more…]
Ronawk Brings On Dr. David S. Zamierowski As New Member of the Board of Directors
March 10, 2023, Olathe, KS – Ronawk, a biotech and biofabrication company powered by the Bio-Block UniverseTM, is pleased to announce the appointment of Dr. David S. Zamierowski to its Board of Directors. Dr. Zamierowski has a storied career as both a Plastic Surgeon and Inventor. He has developed countless advancements in many areas of life science. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 97
- Next Page »